Profile data is unavailable for this security.
About the company
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.
- Revenue in USD (TTM)10.09m
- Net income in USD-47.92m
- Incorporated2014
- Employees29.00
- LocationSpruce Biosciences Inc611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (415) 655-4168
- Fax+1 (302) 636-5454
- Websitehttp://www.sprucebiosciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acasti Pharma Inc | 0.00 | -38.77m | 28.48m | 32.00 | -- | 0.4403 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 29.57m | 255.00 | -- | 0.165 | -- | 10.16 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 29.59m | 7.00 | -- | 1.20 | -- | 50.74 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Aptorum Group Ltd | 1.20m | -13.40m | 29.60m | 18.00 | -- | 1.28 | -- | 24.67 | -3.64 | -3.64 | 0.3234 | 4.22 | 0.0624 | 74.87 | 17.36 | 66,656.11 | -80.15 | -42.74 | -68.67 | -46.93 | 7.33 | -2.90 | -1,283.55 | -1,477.58 | 1.32 | -94.53 | 0.0066 | -- | -15.95 | -- | 60.88 | -- | -42.83 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 29.69m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -10.23m | 30.42m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 30.52m | 29.00 | -- | 0.3977 | -- | 3.02 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| DURECT Corp | 8.55m | -27.62m | 30.73m | 58.00 | -- | 2.03 | -- | 3.59 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Dare Bioscience Inc | 2.81m | -30.16m | 31.38m | 23.00 | -- | -- | -- | 11.18 | -0.3444 | -0.3444 | 0.032 | -0.0505 | 0.0863 | -- | 2.12 | 122,082.20 | -92.65 | -109.51 | -463.87 | -246.26 | -- | -- | -1,074.17 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 31.49m | 8.00 | 104.17 | 14.59 | 59.49 | 5.26 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 31.75m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Surrozen Inc | 0.00 | -43.04m | 32.31m | 42.00 | -- | 0.5493 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -51.06m | 32.99m | 40.00 | -- | 2.55 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rock Springs Capital Management LPas of 25 Mar 2024 | 2.61m | 6.34% |
| Armistice Capital LLCas of 31 Dec 2023 | 2.23m | 5.42% |
| AIGH Capital Management LLCas of 31 Dec 2023 | 2.12m | 5.16% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 1.51m | 3.67% |
| Aisling Capital Management LPas of 31 Dec 2023 | 1.21m | 2.93% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 822.39k | 2.00% |
| DAFNA Capital Management LLCas of 31 Dec 2023 | 548.51k | 1.33% |
| Worth Venture Partners LLCas of 31 Dec 2023 | 526.93k | 1.28% |
| Millennium Management LLCas of 31 Dec 2023 | 510.44k | 1.24% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 400.00k | 0.97% |
